Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 7/20 | 0.35 |
| ▸ | NMT2 | O60551 | 4/20 | 0.35 |
| ▸ | NMT1 | P30419 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18524096 | 0.88 | ADRB2 (0.39) | KDM4EADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL6128441 | 0.85 | FAAH (0.38) | FAAHTSHRNPC1KMT2A | |
| SCHEMBL9290150 | 0.84 | FAAH (0.36) | FAAHTSHRRECQLKMT2A | |
| SCHEMBL16299348 | 0.82 | FAAH (0.36) | POLBFAAHTSHRMEN1NPC1 | |
| SCHEMBL16299342 | 0.80 | FAAH (0.34) | POLBFAAHKDM4ETSHRKMT2A | |
| SCHEMBL9289915 | 0.80 | LMNA (0.39) | FAAHRAB9ATSHRNPC1KMT2A | |
| SCHEMBL9290217 | 0.79 | TSHR (0.38) | KDM4EGAATSHRMEN1KMT2A | |
| SCHEMBL9289334 | 0.79 | FAAH (0.35) | POLBFAAHNPC1KMT2A | |
| SCHEMBL18602758 | 0.78 | FAAH (0.39) | FAAHTSHRNPC1KMT2A | |
| SCHEMBL6128438 | 0.78 | FAAH (0.37) | FAAHGAATSHRNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010129057-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | POLB 3278/4885FAAH 4449/4885NMT2 830/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | POLB 3278/4885FAAH 4449/4885NMT2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.